PNNL

Abstract

The age-related decline in skeletal muscle mass and function is known as sarcopenia. Sarcopenia progresses based on complex processes involving protein dynamics, cell signaling, and oxidative stress and repair. We have previously found that 8-week treatment with elamipretide is capable of improving skeletal muscle function, reversing redox stress, and restoring protein S-glutathionylation labeling in aged female mice. This study tested whether 8-week treatment with elamipretide altered global phosphorylation in skeletal muscle consistent with functional improvements and S-glutathionylation. We found that phosphorylation changes did not relate to S-glutathionylation modifications, but that treatment with elamipretide did partially reverse age-related phosphorylation changes in female skeletal muscle.